These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 20505523)

  • 1. Reduction in the intensity rate of appropriate shocks for ventricular arrhythmias with statin therapy.
    Beri A; Contractor T; Gardiner JC; Ardhanari S; Thakur R
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):190-4. PubMed ID: 20505523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins reduce appropriate implantable cardioverter-defibrillator shocks in ischemic cardiomyopathy with no benefit in nonischemic cardiomyopathy.
    Contractor T; Beri A; Gardiner J; Ardhanari S; Thakur R
    Am J Ther; 2012 Nov; 19(6):413-8. PubMed ID: 22185754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
    Vyas AK; Guo H; Moss AJ; Olshansky B; McNitt SA; Hall WJ; Zareba W; Steinberg JS; Fischer A; Ruskin J; Andrews ML;
    J Am Coll Cardiol; 2006 Feb; 47(4):769-73. PubMed ID: 16487843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy.
    Desai H; Aronow WS; Tsai FS; Ahn C; Lai HM; Amin H; Gandhi K; Frishman WH; Cohen M; Sorbera C
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):176-9. PubMed ID: 19617418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ventricular proarrhythmic effects of atrial fibrillation are modulated by depolarization and repolarization anomalies in patients with left ventricular dysfunction.
    Lemola K; Khan R; Nattel S; Talajic M; Roy D; Guerra PG; Lemola S; Dubuc M; Thibault B; Macle L; Khairy P
    Pacing Clin Electrophysiol; 2009 Jan; 32(1):99-105. PubMed ID: 19140919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy.
    Bhavnani SP; Coleman CI; White CM; Clyne CA; Yarlagadda R; Guertin D; Kluger J
    Europace; 2008 Jul; 10(7):854-9. PubMed ID: 18495672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.
    Corrado D; Calkins H; Link MS; Leoni L; Favale S; Bevilacqua M; Basso C; Ward D; Boriani G; Ricci R; Piccini JP; Dalal D; Santini M; Buja G; Iliceto S; Estes NA; Wichter T; McKenna WJ; Thiene G; Marcus FI
    Circulation; 2010 Sep; 122(12):1144-52. PubMed ID: 20823389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Dickinson MG; Ip JH; Olshansky B; Hellkamp AS; Anderson J; Poole JE; Mark DB; Lee KL; Bardy GH;
    Am Heart J; 2007 Apr; 153(4):573-8. PubMed ID: 17383296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable cardioverter-defibrillator shocks in patients with a left ventricular assist device.
    Ambardekar AV; Allen LA; Lindenfeld J; Lowery CM; Cannon AP; Cleveland JC; Brieke A; Sauer WH
    J Heart Lung Transplant; 2010 Jul; 29(7):771-6. PubMed ID: 20347337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator.
    Chiu JH; Abdelhadi RH; Chung MK; Gurm HS; Marrouche NF; Saliba WI; Natale A; Martin DO
    Am J Cardiol; 2005 Feb; 95(4):490-1. PubMed ID: 15695135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure.
    Desai H; Aronow WS; Ahn C; Gandhi K; Hussain S; Lai HM; Sharma M; Frishman WH; Cohen M; Sorbera C
    Am J Cardiol; 2010 May; 105(9):1336-8. PubMed ID: 20403488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis.
    Wanahita N; Chen J; Bangalore S; Shah K; Rachko M; Coleman CI; Schweitzer P
    Am J Ther; 2012 Jan; 19(1):16-23. PubMed ID: 20720485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy.
    Goldberger JJ; Subacius H; Schaechter A; Howard A; Berger R; Shalaby A; Levine J; Kadish AH;
    J Am Coll Cardiol; 2006 Sep; 48(6):1228-33. PubMed ID: 16979011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator.
    Korte T; Köditz H; Niehaus M; Paul T; Tebbenjohanns J
    Pacing Clin Electrophysiol; 2004 Jul; 27(7):924-32. PubMed ID: 15271011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
    J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction.
    Coleman CI; Kluger J; Bhavnani S; Clyne C; Yarlagadda R; Guertin D; White CM
    Heart Rhythm; 2008 Apr; 5(4):507-10. PubMed ID: 18362016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study.
    Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A;
    Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.